United States · Industrial & Consumer Products · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average
Sector average (own scale)
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Revolution Medicines, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
| ROE | -58.07% | -106.11% | - | 94.46% | 48.84% | 35.07% |
|---|---|---|---|---|---|---|
| Sector average | -229.04% | -10.73% | -40.81% | 47.95% | 47.89% | 72.08% |
| ROA | -46.06% | -52.19% | -56.83% | -56.47% | -56.88% | -61.62% |
| Total Assets | $2,354,508.00K | $1,979,278.43K | $1,979,278.43K | $1,979,278.43K | $1,979,278.43K | $1,979,278.43K |
| Sector average | $13,470,792.03K | $13,845,953.11K | $15,738,337.67K | |||
| Net Income | -$1,131,301.00K | -$1,130,936.91K | -$1,124,813.93K | -$1,117,745.58K | -$1,125,829.72K | -$1,219,598.64K |
| $19,113,394.36K |
| $22,282,552.11K |
| $24,814,255.84K |